Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon

References

• Kloner RA, Ganote CE, Jenning RB. The ‘no-reflow’ phenomenon after temporary coronary occlusion in dogs. J Clin Invest. 1974; 54: 1496–508
   PubMed Web of Science ®Google Scholar
• Kloner RA. Does reperfusion injury exist in humans?. J Am Coll Cardiol. 1993; 21: 537–45
   PubMed Web of Science ®Google Scholar
• Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656–62
   PubMed Web of Science ®Google Scholar
• Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the ‘no-reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223–8
   PubMed Web of Science ®Google Scholar
• Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long term outcome in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 2000; 36: 1202–9
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997; 30: 1193–9
   PubMed Web of Science ®Google Scholar
• Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002; 57: 444–51
   PubMed Web of Science ®Google Scholar
• Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effect of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154–9
   PubMed Web of Science ®Google Scholar
• Limbruno U, Micheli A, De Carlo M, Amoroso G, Rossini R, Palagi C, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003; 108: 171–6
   PubMed Web of Science ®Google Scholar
• Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99: 2720–32
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998; 98: 2695–701
   PubMed Web of Science ®Google Scholar
• Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute myocardial infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24: 67–76
   PubMed Web of Science ®Google Scholar
• van't Hof AWJ, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302–6
   PubMed Web of Science ®Google Scholar
• Gibson MC, Schomig A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096–105
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. Rescue’ utilization of abciximab for the dissolution of thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol. 1997; 30: 1729–34
   PubMed Web of Science ®Google Scholar
• Marzilli M, Sambuceti G, Testa R, Fedele S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol. 2002; 40: 2102–9
   PubMedGoogle Scholar
• Sezer M, Oflaz H, Gören T, Okçular I, Umman B, Nişanci Y, et al. Intracoronary streptokinase after primary percutaneous intervention. N Engl J Med. 2007; 356: 1823–34
   PubMed Web of Science ®Google Scholar
• Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Circulation 1998; 98: 734–41
   PubMed Web of Science ®Google Scholar
• Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. ADMIRAL investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344: 1895–903
   PubMed Web of Science ®Google Scholar
• de Queiroz Fernandes Araujo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trial. Am Heart J. 2004; 148: 937–43
   PubMedGoogle Scholar
• De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjuncitve therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293: 1759–65
   PubMed Web of Science ®Google Scholar
• Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004; 292: 362–6
   PubMed Web of Science ®Google Scholar